1173933-75-9

Upstream product

• 70471-01-1 C₁₉H₂₁NO₄ 
• 138908-56-2 (S)-(+)-2-tert-butoxycarbonylamino-3-(3,4-dimethoxyphenyl)propionic acid methyl ester 
• 59-92-7 levodopa 
• 128595-72-2 (S)-methyl 2-(benzyloxycarbonylamino)-3-(3,4-dimethoxyphenyl)propanoate 
• 73404-23-6 N-benzyloxycarbonyl-3,4-dimethoxy-L-phenylalanine 

Downstream Products

• 1449406-13-6 C₂₈H₃₃ClNO₃Ru 

Relevant academic research and scientific papers

Anticancer activity of ruthenium(II) arene complexes bearing 1,2,3,4-tetrahydroisoquinoline amino alcohol ligands

Ruthenium complexes offer potential reduced toxicity compared to current platinum anticancer drugs. 1,2,3,4-tetrahydrisoquinoline amino alcohol ligands were synthesised, characterised and coordinated to an organometallic Ru(II) centre. These complexes were evaluated for activity against the cancer cell lines MCF-7, A549 and MDA-MB-231 as well as for toxicity in the normal cell line MDBK. They were observed to be moderately active against only the MCF-7 cells with the best IC50 value of 34 μM for the cis-dia-stereomeric complex C4. They also displayed excellent selectivity by being relatively inactive against the normal MDBK cell line with SI values ranging from 2.3 to 7.4.

An organogel formed from a cyclic β-aminoalcohol

A new organogelator with unique structural feature of a cyclic β-aminoalcohol is presented as the first example of gelation by aminoalcohol through hydrogen-bonding between hydroxy and amine.